Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RAD51D V200* |
| Therapy | Olaparib |
| Indication/Tumor Type | triple-receptor negative breast cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RAD51D V200* | triple-receptor negative breast cancer | sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) treatment inhibited viability of triple-negative breast cancer cells expressing RAD51D V200* in culture (PMID: 33151324). | 33151324 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33151324) | Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer. | Full reference... |